Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis

Journal of Clinical Pathology

Volumn 66, Issue 8, 2013, Pages 649-654

  Shafi, Hedyeh ^a   Astvatsaturyan, Kristine ^a   Chung, Fai ^a   Mirocha, James ^a   Schmidt, Michael ^a   Bose, Shikha ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; MONOCLONAL ANTIBODY KI 67; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CHROMOSOME 17; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORPHOLOGICAL TRAIT; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL;

BREAST CANCER; CANCER GENETICS; GENE AMPLIFICATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENETIC HETEROGENEITY; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MIXED TUMOR, MALIGNANT; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2;

EID: 84880580688     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201403     Document Type: Article

References (32)

1. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node negative breast cancer. Cancer Res 1991;51:556-67.
2. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
3. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
4. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
5. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
6. Ring A, Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: Clinical implications. Clin Breast Cancer 2003;4:S34-41.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
8. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-12.
9. Yang YL, Fan Y, Lang RG, et al. Genetic Heterogeneity of HER2 in breast cancer: Impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat 2012;134:1095-102.
10. Ohlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 2011;64:1112-16.
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-22.
12. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
13. Cheang MC, Chia SK, Voduc D, et al. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
14. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: Evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131:678-82.
15. Chang MC, Malowany JI, Mazurkiewicz J, et al. 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: A study of 2522 cases. Mod Pathol 2012;25:683-8.
16. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in bresat cancer: Its clinicopathilogical significance. Mod Pathol 2012;25:938-48.
17. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: Impact of patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-74.
18. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194: 23-8.
19. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
20. Anderson GR, Stoler DL, Brenner BM. Cancer: The evolved consequence of a destabilized genome. Bioessays 2001;23:1037-46.
21. Fujii H, Marsh C, Cairns P, et al. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-7.
22. Carlsson J, Nordgren H, Sjöström J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8.
23. Dikicioglu E, Barutca S, Meydan N, et al. Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes. Int J Clin Pract 2005;59:1039-44.
24. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
25. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30:259-65.
26. Simon R, Nocito A, Hübscher T, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-46.
27. Xu R, Perle MA, Inghirami G, et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-24.
28. Aitken SJ, Thomas JS, Langdon SP, et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010;21:1254-61.
29. Macfarlane R, Seal M, Speers C, et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012;17:172-8.
30. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-6.
31. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-11.
32. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2 positive breast cancer [abstract]. J Clin Oncol 2007;25:P512.